Mechelen (Belgium), January 8th, 2014 – Biocartis, an innovative molecular diagnostics company, today announced its CEO Rudi Pauwels will present at the 33rd Annual J.P. Morgan Healthcare Conference. Pauwels’ presentation will highlight recent accomplishments, including the launch of Biocartis’ flagship platform Idylla™, and the company’s future plans.
Practical information:
Date: Wednesday January 14th 2015
Time: 03.00 p.m. PST
Venue: Elizabethan D Room at Westin St. Francis Hotel, San Francisco, CA.
-end-
About Biocartis (www.biocartis.com)
Biocartis strives to transform the global diagnostics market by providing instant access to personalized medicine for patients worldwide. The company develops fully integrated and broadly applicable molecular diagnostic solutions that can be used in a wide variety of healthcare settings to provide rapid, high-quality care to patients. Biocartis is working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in different disease areas. Biocartis has set up in-house commercial scale manufacturing capabilities at its premises in Mechelen (near Brussels). The Idylla™ system and its first oncology assay, the IdyllaTM BRAF Mutation Test, have obtained CE-IVD marking.
About Idylla™ (www.idylla.com)
Biocartis has developed a miniaturized, fully automated molecular system that integrates all molecular diagnostic steps in one easy-to-use system. Idylla™ offers clinicians fast and easy access to molecular diagnostics information, anywhere and anytime. It can be used for any human clinical sample type and covers the entire process from sample to result in a time frame of 40 to 150 minutes. Idylla™ enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond. Idylla™ and the system’s first assay, the Idylla™ BRAF Mutation Test, have obtained CE-IVD marking.
Help employers find you! Check out all the jobs and post your resume.
